Business Wire

ZAYED-SUSTAINABILITY

15.3.2022 14:36:12 CET | Business Wire | Press release

Share
Zayed Sustainability Prize Opens Submissions for 2023 Cycle

The Zayed Sustainability Prize, the UAE’s pioneering global award for recognising organisations and high schools with sustainability solutions, has officially announced that the 2023 cycle is now open for submissions.

Entries will be accepted until 6 July 2022 through the Prize’s online portal. Small to medium enterprises, non-profit organisations and high schools with sustainability solutions are invited to submit an entry for consideration in one of the five categories of Heath, Food, Energy, Water and Global High Schools.

The Prize’s 2022 award cycle received a record-breaking 4,000 applications, marking a significant 68.5% increase in submissions compared to the previous cycle, from a record 151 countries.

Commenting on the launch of the 2023 submissions cycle, H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Zayed Sustainability Prize said: “For the past 14 years, the Prize has proudly delivered on its goal of recognising and rewarding the achievements of those who are driving impactful, innovative and inspiring sustainability solutions. As we continue to build on this legacy, we look forward to awarding the next cadre of sustainability pioneers, who will drive real environmental and social change and generate an even greater positive impact on the world.”

H.E. Al Jaber added, “Young people remain an integral focus for the Prize and we are committed to empowering even greater numbers of future sustainability leaders by providing them with a platform to turn their bold ideas into reality through our Global High Schools category.”

“The Zayed Sustainability Prize continues to be a steadfast partner and thought leader in international sustainable development. By amplifying the critical work being done globally in health, energy, food and water, and facilitating the delivery of these solutions to vulnerable communities around the world through the Prize winners, we have helped transform the lives of more than 370 million people.”

The Prize’s US$3 million annual fund rewards winners US$600,000 in each category. The Global High Schools category is split into six world region winners, with each school able to claim up to US$100,000 to start or further expand their project. The six world regions of the Global High Schools category are The Americas, Europe & Central Asia, Middle East & North Africa, Sub-Saharan Africa, South Asia, and East Asia & Pacific.

Inspired by the sustainability and humanitarian legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, the Prize has, to date, recognised a total of 96 winners whose solutions or student-led school projects have positively transformed the lives of millions.

While the submission forms vary per category, core elements of each entry lie in the innovative, impactful and inspirational ways in which the proposed technology, applications and solutions aim to transform people’s lives for the better.

For the Health, Food, Energy, and Water categories, organisations should demonstrate that they are improving access to essential products or services and have a long-term vision for improved living and working conditions. For the Global High Schools category, their projects should be student–led, with emphasis placed on the students being actively involved in the planning, implementation, and monitoring processes.

The Zayed Sustainability Prize has a three-stage evaluation process, beginning with the due diligence conducted by an independent research and analysis consultancy. This identifies the qualified entries and results in the selection of eligible candidates. Following this, evaluations are undertaken by a Selection Committee consisting of category-specific panels of independent international experts. From this shortlist of candidates, the finalists are chosen and then sent to the Prize Jury who unanimously elect the winners, across all five categories.

Winners will be announced in 2023 during an Awards Ceremony as part of the Abu Dhabi Sustainability Week (ADSW).

For more information, visit www.ZayedSustainabilityPrize.com

About the Zayed Sustainability Prize

Established by the UAE leadership, in 2008, to honour the legacy of the founding father, the late Sheikh Zayed bin Sultan Al Nahyan, the Zayed Sustainability Prize is the UAE’s pioneering global award for sustainability and humanitarian solutions around the world.

The Zayed Sustainability Prize recognises and rewards small to medium-sized enterprises (SMEs), non-profit organisations (NPOs), and global high schools, that are committed to accelerating impactful sustainable solutions.

Over the past 14 years, the Prize has awarded 96 winners. Collectively, they have positively impacted the lives of more than 370 million people around the world. The Zayed Sustainability Prize categories are Health, Food, Energy, Water and Global High Schools.

For more information, please visit www.ZayedSustainabilityPrize.com or go to our social media platforms on, Twitter , Facebook , Instagram , YouTube .

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye